Clinical Trials
25
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (23 trials with phase data)• Click on a phase to view related trials
Obe-cel in Severe, Refractory Systemic Lupus Erythematosus With Active Lupus Nephritis
- Conditions
- Lupus Nephritis
- Interventions
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Autolus Limited
- Target Recruit Count
- 35
- Registration Number
- NCT07053800
Expanded Access Program for OOS Obe-cel
- Conditions
- Lymphoblastic Leukemia, Acute, AdultB Cell ALL
- First Posted Date
- 2025-01-29
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Autolus Limited
- Registration Number
- NCT06799221
A Study of CD19 Targeted CAR T Cell Therapy in Patients With Severe, Refractory Systemic Lupus Erythematosus (SLE)
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Biological: Obecabtagene autoleucel (obe-cel)
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Autolus Limited
- Target Recruit Count
- 12
- Registration Number
- NCT06333483
- Locations
- 🇪🇸
Hospital Universitari Vall Hebrón, Barcelona, Spain
🇬🇧University College London Hospitals NHS Foundation Trust, London, United Kingdom
🇬🇧Manchester Royal Infirmary, Manchester University NHS Foundation Trust,, Manchester, United Kingdom
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- Conditions
- Relapsed or Refractory B Cell Non-Hodgkin LymphomaRelapsed or Refractory B Cell Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Autolus Limited
- Target Recruit Count
- 30
- Registration Number
- NCT06173518
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇬🇧Royal Manchester Children's Hospital, Manchester, United Kingdom
🇺🇸Methodist Children's Hospital, San Antonio, Texas, United States
An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia.
- Conditions
- Relapsed or refractory B cell acute lymphoblastic leukaemia
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Autolus Limited
- Target Recruit Count
- 17
- Registration Number
- 2024-512903-38-00
- Locations
- 🇪🇸
Hospital Universitari Vall D Hebron, Barcelona, Spain
🇪🇸Hospital Universitario Y Politecnico La Fe, Valencia, Spain
🇪🇸University Hospital Virgen Del Rocio S.L., Sevilla, Spain
- Prev
- 1
- 2
- Next
News
Advancements in Acute Lymphocytic Leukemia (ALL) Treatment Landscape
The FDA approved obecabtagene autoleucel (Aucatzyl) for adults with relapsed or refractory B-cell precursor ALL, marking a significant advancement in CAR T-cell therapy.
CAR T-cell Therapy Shows Promise in Treating Severe Lupus in UK Trial
Three patients in the UK have received CAR T-cell therapy for severe lupus, a potentially life-threatening autoimmune disease.
CAR T-Cell Therapy Shows Promise in Treating Severe Lupus in UK Trial
Three patients in the UK have received CAR T-cell therapy for severe lupus, offering a potential cure and eliminating the need for lifelong medication.
CAR T-cell Therapy Shows Promise in Treating Severe Lupus
Three UK patients have received CAR T-cell therapy for severe lupus, offering hope for a potential cure and eliminating the need for lifelong medication.
CAR T-Cell Therapy Shows Promise in Treating Severe Lupus in UK Trial
Three patients in the UK have received CAR T-cell therapy for severe lupus, a potentially life-threatening autoimmune condition, in a new NHS trial led by UCLH and UCL.
Biotech Spin-outs Emerge as Critical Bridge Between Academia and Pharma R&D
Big Pharma's traditional R&D model is shifting towards external innovation, with universities and biotech spin-outs becoming essential players in drug development ecosystem.